Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer(Dana-Farber Cancer Institute), Oleg Lipatov(Republican Oncological Clinical Dispensary), Seock‐Ah Im(Seoul National University), Anthony Gonçalvès(Aix-Marseille Université), Eva Muñoz‐Couselo(Vall d'Hebron Institute of Oncology), Keun Seok Lee(National Cancer Center), Peter Schmid(Queen Mary University of London), Kenji Tamura, Laura Testa(Instituto do Câncer do Estado de São Paulo), Isabell Witzel(University Medical Center Hamburg-Eppendorf), Shoichiro Ohtani(Hiroshima City Asa Citizens Hospital), Nicholas C. Turner(National Health Service), Stefania Zambelli(IRCCS Ospedale San Raffaele), Nadia Harbeck(Ludwig-Maximilians-Universität München), Fabrice André(Institut Gustave Roussy), Rebecca Dent(National Cancer Centre Singapore), Xuan Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vassiliki Karantza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jaime Mejia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Javier Cortés(GEICAM – Spanish Breast Cancer Group)
Cited by 488
Abstract
Related Papers
No related papers found
Powered by citation graph analysis